<DOC>
	<DOCNO>NCT02428088</DOCNO>
	<brief_summary>This 6 week efficacy safety study Dasotraline subject 6 12 year old ADHD .</brief_summary>
	<brief_title>Dasotraline Pediatric ADHD Study</brief_title>
	<detailed_description>This randomize , double blind , multicenter , placebo-controlled , parallel group , outpatient study evaluate efficacy safety dasotraline subject 6 12 year age ADHD use 2 dos dasotraline ( 2 mg/day 4 mg/day ) versus placebo 6 week treatment period . The study consist screening , treatment , end study visit .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Subject 's parent/legal guardian must give write informed consent , include privacy authorization , prior study participation . The subject complete inform assent prior study participation . Subject subject 's parent/legal guardian must judge investigator willing able comply study procedure visit schedule . Subject , male female , must 6 12 year age , inclusive , time consent/assent Baseline . Subject meet Diagnostic Statistical Manual Mental Disorders Fifth Edition ( DSM 5 ) criterion primary diagnosis ADHD ( inattentive , hyperactive , combined presentation ) screen establish comprehensive psychiatric evaluation review DSM 5 criterion confirm use KSADSPL Screening . Subject ADHD RS IV HV score ≥ 28 . Subject CGI S score ≥ 4 . Subject , female , must pregnant breastfeeding , ≥ 8 year age must negative pregnancy test . Female subject : must unable become pregnant ( eg , premenarchal , surgically sterile , etc ) ; OR • practice true abstinence ( consistent lifestyle ) must agree remain abstinent signing inform consent/assent least 14 day last dose study drug take ; OR • sexually active willing use medically effective method birth control ( see Appendix VII ) signing inform consent/assent least 14 day last dose study drug take . Male subject must willing remain sexually abstinent ( consistent lifestyle ) use effective method birth control signing inform consent/assent least 14 day last dose study drug take . Subject must general good health ( define absence clinically relevant abnormality determine Investigator ) base screen physical neurological examination , vital sign , medical history , clinical laboratory value ( hematology , chemistry , urinalysis ) . Note : If hematology , chemistry , urinalysis result within laboratory 's reference range , subject may include investigator determines deviation clinically relevant . Subject weigh least 21 kg within 3rd 97th percentile gender specific bodymassindex ( BMI ) forage World Health Organization ( WHO ) growth chart ( see Appendices II IX ) . Subject 's parent/legal guardian must report history subject able swallow capsule . Subject subject 's parents/legal guardian must able fully comprehend informed consent/assent form ( applicable ) , understand study procedure , able communicate satisfactorily Investigator study coordinator . Subject parent/legal guardian commitment study would interfere attend study visit . Subject currently diagnosis asthma required daily treatment bronchodilator nebulizer treatment 30 day prior screen and/or may require daily treatment agent course trial . Intermittent use bronchodilator exclusionary . Subjects history require persistent asthma treatment discuss wit medical monitor prior enrolment . Subject clinically significant unstable medical abnormality , chronic disease , history clinically significant abnormality cardiovascular , gastrointestinal , respiratory , hepatic , renal system , disorder history condition ( eg , malabsorption , gastrointestinal surgery ) may interfere drug absorption , distribution , metabolism , excretion . Note : Active medical condition minor wellcontrolled exclusionary affect risk subject study result . In case impact condition upon risk subject study result unclear , Medical Monitor consult . Any subject know cardiovascular disease condition ( even control ) must discuss Medical Monitor screening . Subject history presence abnormal ECGs , investigator 's opinion clinically significant . Screening site ECGs centrally overread , eligibility determine investigator base result overread report . Subject documented diagnosis Bipolar I II Disorder , major depressive disorder , conduct disorder , obsessivecompulsive disorder , disruptive mood dysregulation disorder ( DMDD ) , intellectual disability , history psychosis , autism spectrum disorder , Tourette 's Syndrome , confirm genetic disorder cognitive and/or behavioral disturbance . Note : Subjects oppositional defiant disorder ( ODD ) permit enroll study long ODD primary focus treatment . Subject generalized anxiety disorder primary focus treatment time 12 month prior screen require pharmacotherapy time 6 month prior screen . Subject fail 2 adequate course stimulant nonstimulant treatment ADHD , judge investigator . Subject evidence chronic disease central nervous system ( CNS ) tumor , inflammation , seizure disorder , vascular disorder , potential CNS relate disorder might occur childhood ( eg , Duchenne Muscular dystrophy , myasthenia gravis , neurologic serious neuromuscular disorder ) , history persistent neurological symptom attributable serious head injury . Past history febrile seizure , druginduced seizure , alcohol withdrawal seizure exclusionary . Subject take anticonvulsant seizure control currently within past 2 year eligible study participation . Subject uncontrolled thyroid disorder indicate free T4 , free T3 , thyroid stimulate hormone ( TSH ) outside limit normal reference laboratory . Subject answer `` yes '' `` Suicidal Ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) lifetime history C SSRS Children 's Lifetime/Recent assessment screening . Subject history attempt suicide , opinion investigator . Subject tolerate venipuncture poor venous access would cause difficulty collect blood sample . Subject history severe allergies 1 class medication multiple adverse drug reaction history allergic reaction know suspected sensitivity substance contain study drug formulation . Subject history intolerance stimulant . Subject take antipsychotic medication within 8 week prior screen . Subject take medication , include health food supplement purport psychotropic activity ( example , St. John 's Wort ) , must minimum washout 7 day prior Day 1 . Subject take antidepressant medication ( eg , bupropion , selective serotonin reuptake inhibitor [ SSRI ] / serotonin norepinephrine reuptake inhibitor [ SNRI ] , monoamine oxidase [ MAO ] inhibitor , tricyclic , etc ) must minimum washout 7 day prior Day 1 . Subject currently undergo Cognitive Behavioral Therapy ( CBT ) treatment ADHD , initiated behavioral therapy ( include school base intervention ) less 1 month prior screening , receive behavioral therapy opinion investigator able follow stable routine duration study . Subject subject 's family anticipate move outside geographic range investigative site study period , plan extend travel inconsistent recommend visit interval study duration . Subject history , current malignancy except non melanomatous skin cancer . Subject history positive test Hepatitis B surface antigen Hepatitis C antibody liver function test result screen upper limit normal reference laboratory . Subject know tested positive human immunodeficiency virus ( HIV ) . Subject participate investigational study within 90 day prior screen currently participate another clinical trial . Subject history substance alcohol use disorder ( exclude caffeine ) within 12 month prior screen , define DSM 5 criterion , currently use tobacco nicotinecontaining product , positive urine drug screen ( UDS ) breath alcohol test screening . Note : Subjects positive UDS may allow continue study , provide investigator determines positive test result take prescription medicine ( ) prescribe . Subject require treatment disallow medication study . Subject experience significant blood loss within 60 day prior screen . Subject previously enrol clinical trial dasotraline ( SEP 225289 ) . Subject 's parent/legal guardian investigational site staff member relative investigational site staff member . Subject , opinion Investigator , unsuitable way participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>